Praxis Bioresearch, a biopharmaceutical company focused on the discovery and development of novel therapeutics for chronic neuropsychiatric and neurodegenerative disorders, today announced that it has been awarded a Fast-Track Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). The $1.5 million award will support the ongoing development of the company’s lead product candidate, PRX-P4-003, a prodrug stimulant with abuse deterrent properties.

PRX­P4­003 is a novel, abuse-deterrent dopamine norepinephrine reuptake inhibitor incorporating an active isomer of fencamfamine (FCF), a well-tolerated Schedule IV stimulant.  Fencamfamine has a long-established clinical profile following decades of therapeutic use in Europe and other countries, where it was primarily prescribed for depressive daytime fatigue, lack of concentration, and lethargy.

Read more at www.globenewswire.com